New Research Shows Significant Benefits for COPD Patients in the Home Using Fisher Paykel Healthcare#s myAirvo

Food and Healthcare Press Releases Friday April 20, 2018 15:35
AUCKLAND, New Zealand--20 Apr--PRNewswire/InfoQuest

Fisher & Paykel Healthcare Corporation Limited announced today that new research has been published in the International Journal of COPD which demonstrates significant benefits of nasal high flow therapy for COPD* patients using Fisher & Paykel Healthcare's myAirvo device.

The study[1], a randomised controlled trial undertaken in Denmark, investigated the long-term effects of nasal high flow therapy for COPD patients already being treated with long-term oxygen therapy.

The trial showed statistically significant results, with the primary outcome being a significant reduction in patients' exacerbation rate, or worsening of their condition (from 4.95 to 3.12 per patient per year, p is less than 0.001) for those being treated with nasal high flow therapy.

The study also showed for those patients using the myAirvo, that all cause hospitalisation rates decreased from a rate of 1.39 to 0.79 per patient, over the course of the year, for those who followed the protocol. Other positive results included the treatment group (myAirvo) being better than the control group (standard care) in several quality of life assessments, less breathlessness, better mobility and lower carbon dioxide retention levels for these chronic patients.

The trial is the largest study of this treatment length to have been conducted in a home environment and was led by researchers Line Storgaard and Dr Ulla Weinreich. It followed 200 patients with COPD on long-term oxygen for 16 hours or more per day over a period of one year.

Vice President - Products & Technology at Fisher & Paykel Healthcare, Andrew Somervell said, "It is positive to see such convincing outcomes for patients with COPD. We expect this study to increase clinical interest in the myAirvo home respiratory device and encourage clinical change and adoption around the world."

This study adds to other positive results that were recently published in the Annals of the American Thoracic Society. Led by Dr Kazuma Nagata of Kobe City Medical Centre General Hospital, this study was a multi-centre trial in Japan with cross-over design, studying stable COPD patients with hypercapnia[2]. This research also demonstrated a clinically significant improvement in quality of life for patients (the mean total score improved by 7.8 points, p is less than 0.01), and a decrease in hypercapnia levels for patients with stable hypercapnic COPD.

As a result of the positive outcomes of this pilot trial, a larger multi-centre trial has commenced.
Together, these new studies add to the growing body of evidence showing the efficacy of nasal high flow therapy in the home for COPD patients using the myAirvo device.
*Chronic Obstructive Pulmonary Disease

[1] Storgaard L, Hockey H, Laursen B, Weinreich U. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. Int J Chron Obstruct Pulmon Dis. 2018;13:1195-1205. Fisher & Paykel Healthcare provided the myAirvo devices and contributed to the funding of this study.

[2] Nagata K, Kikuchi T, Horie T, Shiraki A, Kitajima T, Kadowaki T et al. Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial. Ann Am Thorac Soc. 2018;15(4):432-439.


Latest Press Release

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

NovoEight(R) Maintains Potency When Stored at 40?C Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow,...

The Mall Shopping Center and Government Savings Bank Co-host The Mall Health Beauty Expo 2018

The Mall Shopping Center, Government Savings Bank, leading hospitals and health institutions are co-hosting an annual grand event, "The Mall Health & Beauty Expo 2018" on June 28 – July 4, 2018 at the Grand Hall, G Floor, The Mall Bangkapi....

Merck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

ASCO Abstract # ERBITUX(R) (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814...

Related Topics